Evidence map›Paper›PMID 29534899›Full record

ReviewInternational journal of radiation oncology, biology, physics2021

Single- and Multi-Fraction Stereotactic Radiosurgery Dose Tolerances of the Optic Pathways.

Michael T Milano, Jimm Grimm, Scott G Soltys, Ellen Yorke, Vitali Moiseenko, Wolfgang A Tomé, Arjun Sahgal, Jinyu Xue, Lijun Ma, Timothy D Solberg and 5 more

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of radiation oncology, biology, physics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed, 9 pooled it
11.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

77 citing papers in PubMed, 9 syntheses or guidelines pooled it, 160 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Reirradiation of recurrent brain tumors: a review by the ESTRO CNS Focus Group.Clinical and translational radiation oncology · 2027
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Trade-offs in proton and photon radiotherapy for pituitary adenomas.Physics and imaging in radiation oncology · 2026
    Article
  18. Article
  19. Article
  20. Review

17 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 12 institutions in 2 countries.

Michael T MilanoDepartment of Radiation Oncology, University of Rochester, Rochester, New York. Electronic address: michael_milano@urmc.rochester.edu.
Jimm GrimmDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Scott G SoltysDepartment of Radiation Oncology, Stanford University Medical Center, Stanford, California.
Ellen YorkeDepartment of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York.
Vitali MoiseenkoDepartment of Radiation Medicine and Applied Sciences, University of California, San Diego, La Jolla, California.
Wolfgang A ToméDepartment of Radiation Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York.
Arjun SahgalDepartment of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
Jinyu XueDepartment of Radiation Oncology, NYU Langone Medical Center, New York, New York.
Lijun MaDepartment of Radiation Oncology, University of California, San Francisco, San Francisco, California.
Timothy D SolbergDepartment of Radiation Oncology, University of California, San Francisco, San Francisco, California.
John P KirkpatrickDepartments of Radiation Oncology and Surgery, Duke Cancer Institute, Durham, North Carolina.
Louis S ConstineDepartment of Radiation Oncology, University of Rochester, Rochester, New York.
John C FlickingerDepartments of Radiation Oncology and Neurosurgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
Lawrence B MarksDepartment of Radiation Oncology, University of North Carolina, Chapel Hill, North Carolina.
Issam El NaqaDepartment of Radiation Oncology, Lineberger Cancer Center, University of North Carolina, Chapel Hill, North Carolina.
University of California, San Francisco · USUniversity of North Carolina at Chapel Hill · USUniversity of Rochester · USDuke Cancer InstituteHealth Sciences Centre · CAJohns Hopkins University · USMemorial Sloan Kettering Cancer Center · USMontefiore Medical Center · USNYU Langone Health · USStanford Medicine · USUniversity of California, San Diego · USUniversity of Pittsburgh Medical Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

purposeDosimetric and clinical predictors of radiation-induced optic nerve/chiasm neuropathy (RION) after single-fraction stereotactic radiosurgery (SRS) or hypofractionated (2-5 fractions) radiosurgery (fSRS) were analyzed from pooled data that were extracted from published reports (PubMed indexed from 1990 to June 2015). This study was undertaken as part of the American Association of Physicists in Medicine Working Group on Stereotactic Body Radiotherapy, investigating normal tissue complication probability (NTCP) after hypofractionated radiation. METHODS AND MATERIALS: Eligible studies described dose delivered to optic nerve/chiasm and provided crude or actuarial toxicity risks, with visual endpoints (ie, loss of visual acuity, alterations in visual fields, and/or blindness/complete vision loss). Studies of patients with optic nerve sheath tumors, optic nerve gliomas, or ocular/uveal melanoma were excluded to obviate direct tumor effects on visual outcomes, as were studies not specifying causes of vision loss (ie, tumor progression vs RION).

resultsThirty-four studies (1578 patients) were analyzed. Histologies included pituitary adenoma, cavernous sinus meningioma, craniopharyngioma, and malignant skull base tumors. Prior resection (76% of patients) did not correlate with RION risk (P = .66). Prior irradiation (6% of patients) was associated with a crude 10-fold increased RION risk versus no prior radiation therapy. In patients with no prior radiation therapy receiving SRS/fSRS in 1-5 fractions, optic apparatus maximum point doses resulting in <1% RION risks include 12 Gy in 1 fraction (which is greater than our recommendation of 10 Gy in 1 fraction), 20 Gy in 3 fractions, and 25 Gy in 5 fractions. Omitting multi-fraction data (and thereby eliminating uncertainties associated with dose conversions), a single-fraction dose of 10 Gy was associated with a 1% RION risk. Insufficient details precluded modeling of NTCP risks after prior radiation therapy.

conclusionsOptic apparatus NTCP and tolerance doses after single- and multi-fraction stereotactic radiosurgery are presented. Additional standardized dosimetric and toxicity reporting is needed to facilitate future pooled analyses and better define RION NTCP after SRS/fSRS.

Indexed as

AdenomaBlindnessCavernous SinusCraniopharyngiomaHumansMaximum Tolerated DoseMeningeal NeoplasmsMeningiomaModels, BiologicalModels, TheoreticalOptic ChiasmOptic NerveOrgans at RiskPituitary NeoplasmsRadiation Dose HypofractionationRadiation Tolerance

Identifiers

PMID29534899
PMCPMC9479557
OpenAlexW2789308048

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.